

Canntab Therapeutics Limited

October 21, 2020

Canadian Securities Exchange
220 Bay Street, 9th Floor
Toronto, Ontario MSJ 2W4

Dear Sirs/Mesdames:

**Re: Canntab Therapeutics Limited (the “Company”)
Asset Purchase Agreements**

Pursuant to Section 3.3 of Policy 6 of the Canadian Securities Exchange, we advise that the Company has completed its asset purchase agreement with CMAX Technologies Inc. (“**CMAX**”) to acquire certain cannabis-processing equipment and leasehold improvements (the “**CMAX Assets**”). The purchase price was satisfied through the issuance of 1,996,078 common shares of the Company (the “**Common Shares**”) at a deemed price of \$0.51 per Common Share.

In addition, the Company closed its binding asset purchase agreement with Pharmagenetics Solutions Inc. (“**Pharma**”) to purchase cannabis-processing equipment (the “**Pharma Assets**”) owned by Pharma (the “**Pharma Transaction**”). The purchase price of the Pharma Assets of \$300,000 was satisfied through the issuance of 588,235 Common Shares at a deemed price of \$0.51 per Common Share.

The shares have been issued accordingly and the acquisition has closed. Title to the Pharma Assets and CMAX Assets have been transferred to Canntab.

The terms of the acquisition are outlined in the Company’s final Form 9 – Notice of Proposed Issuance of Listed Securities dated October 15, 2020.

Yours very truly,

CANNTAB THERAPEUTICS LIMITED

/s/ "Richard Goldstein"

Richard Goldstein
Director & CFO